Volume 4, Issue 3

Treatment Changes for Aging Patients

In this issue:

With many of their patients with MS living beyond 60, 70, and even 80 years of age, clinicians are challenged to better understand the effects of aging on MS patient management. What are the aging-related mechanisms of MS? Where do the symptoms of normal aging and MS overlap? Current research is indicating the risk/benefit of DMTs changes as patients age: should DMTs be discontinued in older patients? If so, at what age? 

These are some of the questions Dr. Burcu Zeydan from the Mayo Clinic’s Department of Neurology and Radiology addresses in this issue of eMS Review.

Learning objectives:

  • Describe the role of aging-related mechanisms in MS disease management.
  • Discuss the benefit-risk ratio in discontinuing disease-modifying treatment in older patients with MS.

Author:

Burcu Zeydan, MD
Burcu Zeydan, MD
Assistant Professor of Neurology and Radiology
Mayo Clinic College of Medicine
Rochester, MN

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: January 6, 2022
Expiration date: January 5, 2025